Four-Year Outcomes of First-Line Nivolumab Plus Ipilimumab for 6 Months Versus Continuation in Patients With Advanced NSCLC: Results of the Randomized IFCT-1701 “DICIPLE” Phase III Trial

Journal of Thoracic Oncology 2026

View at publisher
Authors: G. Zalcman, A. Madroszyk, E. Guenzi, C. Dayen, Olivier Molinier, Thomas Egenod, Nicolas Poté, D. Debieuvre, Sophie Beaucaire-Danel, A. Dixmier, Eric Pichon, Sophie Galland-Girodet
+18 more E. Giroux-Leprieur, Nicolas Cloarec, Jacques Cadranel, Josiane Otto, P. Romand, Laure Favier, Stephanie Martinez, Céline Mascaux, L. Odier, Alexis B. Cortot, C. Audigier-Valette, Alexandra Langlais, Elodie Amour, Franck Morin, M. Antoine, Valérie Gounant, V. Westeel, Anne-Claire Toffart
DOI: 10.1016/j.jtho.2026.103609
Cited by: 3
References: 21

Fields of Study & Subjects

Cancer Immunotherapy and Biomarkers Lung Cancer Treatments and Mutations Lung Cancer Diagnosis and Treatment

Publication details

Journal / source
Journal of Thoracic Oncology
Publisher
Elsevier BV
Volume
21
Issue
6
Pages
103609–103609
Publication date
1 February 2026
Language
EN